(Total Views: 329)
Posted On: 01/30/2020 8:57:07 AM
Post# of 36566
From today on the YMB:
David2 hours ago
Bob not sure why they are talking abort corona virus but they are involved with infectious diseases
ReplyReplies (2)1
Leave a reply
GuidelinesReply
joseph
joseph13 minutes ago
https://www.biospace.com/article/releases/gen...ine-/?s=61
Reply
joseph
joseph14 minutes ago
Also targeting influenza
In addition to cancer protein targets, the company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.
The distinguishing feature of Antigen technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies
David2 hours ago
Bob not sure why they are talking abort corona virus but they are involved with infectious diseases
ReplyReplies (2)1
Leave a reply
GuidelinesReply
joseph
joseph13 minutes ago
https://www.biospace.com/article/releases/gen...ine-/?s=61
Reply
joseph
joseph14 minutes ago
Also targeting influenza
In addition to cancer protein targets, the company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.
The distinguishing feature of Antigen technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies
(1)
(0)
